High COX-2 Immunostaining in Papillary Thyroid Carcinoma is Associated with Adverse Survival Outcomes

Overview

Journal Ann Saudi Med

Specialty General Medicine

Date 2022 Nov 29

PMID 36444921

Authors

Jaudah Ahmed Al-Maghrabi

Wafaey Gomaa

Affiliations

Soon will be listed here.

Abstract

Background: Thyroid carcinoma is one of the most common malignancies worldwide. More than 70%-80% are papillary thyroid carcinoma (PTC). Many factors influence the PTC pathway of development such as genetic mutations, growth factors, and radiation. More biological understanding of the genetic and molecular pathways is needed in PTC to determine tumor behavior, and initial clinical assessment.

Objectives: Investigate the relation of COX-2 immunostaining in thyroid carcinoma with clinicopathological parameters to assess whether immunostaining results have prognostic significance.

Design: Retrospective study SETTING: Pathology department, tertiary care center METHODS: Records of PTC were retrieved and tissue microarrays were constructed. Tissue sections were stained using anti-human COX-2 monoclonal antibody. Immunostaining results were recorded and analysed.

Main Outcome Measures: Relationship of COX-2 immunostaining in thyroid carcinoma with clinicopathological parameters.

Sample Size: 139 tissue samples from 139 patients RESULTS: High versus low COX-2 immunostaining showed no significant differences for most clinicopathological parameters. However, high COX-2 immunostaining showed borderline association with tumor multifocality (=.05), lower overall (log-rank=8.739 and =.003), and disease-free survival (log-rank=7.033, =.008).

Conclusion: The study showed a positive association of high COX-2 immunostaining with lower survival outcomes in PTC. COX-2 immunostaining could be a potential prognostic factor for survival in PTC. Additional molecular and clinical investigations are needed for further understanding the molecular pathways of COX-2 in PTC and the feasibility of using inhibitors of COX-2 as adjuvant therapy along with current chemotherapy.

Limitations: Relatively low number of PTC variants, and no testing of other thyroid carcinomas.

Conflict Of Interest: None.

References

Fu X, Zhang H, Chen Z, Yang Z, Shi D, Liu T . TFAP2B overexpression contributes to tumor growth and progression of thyroid cancer through the COX-2 signaling pathway. Cell Death Dis. 2019; 10(6):397. PMC: 6529436. DOI: 10.1038/s41419-019-1600-7. View

Ruco L, Scarpino S . The Pathogenetic Role of the HGF/c-Met System in Papillary Carcinoma of the Thyroid. Biomedicines. 2017; 2(4):263-274. PMC: 5344270. DOI: 10.3390/biomedicines2040263. View

Al-Maghrabi J, Emam E, Gomaa W, Saggaf M, Buhmeida A, Al-Qahtani M . c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence. BMC Cancer. 2015; 15:676. PMC: 4603921. DOI: 10.1186/s12885-015-1662-6. View

Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J . Expression of cyclooxygenase-2 in prostate carcinoma. Cancer. 2000; 89(3):589-96. View

Giaginis C, Alexandrou P, Delladetsima I, Karavokyros I, Danas E, Giagini A . Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions. Pathol Oncol Res. 2015; 22(1):189-96. DOI: 10.1007/s12253-015-9997-5. View

Al-Maghrabi B, Gomaa W, Abdelwahed M, Al-Maghrabi J . Increased COX-2 Immunostaining in Urothelial Carcinoma of the Urinary Bladder Is Associated with Invasiveness and Poor Prognosis. Anal Cell Pathol (Amst). 2019; 2019:5026939. PMC: 6501277. DOI: 10.1155/2019/5026939. View

Kim K, Kim S, Hyung Kim S, Back J, Park M, Kim J . Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation. J Korean Med Sci. 2006; 21(6):1064-9. PMC: 2721930. DOI: 10.3346/jkms.2006.21.6.1064. View

Lee H, Baek S, Kwon S, Jung K, Chae S, Hwang S . Cyclooxygenase 1 and 2 expressions in the human thyroid gland. Eur Arch Otorhinolaryngol. 2005; 263(3):199-204. DOI: 10.1007/s00405-005-0999-x. View

Specht M, Tucker O, Hocever M, Gonzalez D, Teng L, Fahey 3rd T . Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab. 2002; 87(1):358-63. DOI: 10.1210/jcem.87.1.8179. View

10.

Margulis V, Shariat S, Ashfaq R, Thompson M, Sagalowsky A, Hsieh J . Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol. 2007; 177(3):1163-8. DOI: 10.1016/j.juro.2006.10.033. View

11.

Ji B, Liu Y, Zhang P, Wang Y, Wang G . COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study. Int J Med Sci. 2012; 9(3):237-42. PMC: 3348528. DOI: 10.7150/ijms.4173. View

12.

Prescott S . Is cyclooxygenase-2 the alpha and the omega in cancer?. J Clin Invest. 2000; 105(11):1511-3. PMC: 300865. DOI: 10.1172/JCI10241. View

13.

Tsujii M, DuBois R . Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995; 83(3):493-501. DOI: 10.1016/0092-8674(95)90127-2. View

14.

Erdem H, Gundogdu C, Sipal S . Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma. Exp Mol Pathol. 2011; 90(3):312-7. DOI: 10.1016/j.yexmp.2011.01.008. View

15.

Siironen P, Ristimaki A, Narko K, Nordling S, Louhimo J, Andersson S . VEGF-C and COX-2 expression in papillary thyroid cancer. Endocr Relat Cancer. 2006; 13(2):465-73. DOI: 10.1677/erc.1.01114. View

16.

Larson S, Jackson L, Riall T, Uchida T, Thomas R, Qiu S . Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg. 2007; 204(5):764-73. PMC: 2430882. DOI: 10.1016/j.jamcollsurg.2006.12.037. View

17.

Cornetta A, Russell J, Cunnane M, Keane W, Rothstein J . Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope. 2002; 112(2):238-42. DOI: 10.1097/00005537-200202000-00008. View

18.

Kajita S, Ruebel K, Casey M, Nakamura N, Lloyd R . Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod Pathol. 2004; 18(2):221-7. DOI: 10.1038/modpathol.3800285. View

19.

Mazhar D, Gillmore R, Waxman J . COX and cancer. QJM. 2005; 98(10):711-8. DOI: 10.1093/qjmed/hci119. View

20.

Krawczyk-Rusiecka K, Lewinski A . Cyclooxygenase-2 expression and its association with thyroid lesions. Arch Med Sci. 2012; 6(5):653-7. PMC: 3298330. DOI: 10.5114/aoms.2010.17076. View